Atossa Therapeutics Inc. (NASDAQ:ATOS) saw a downside of -1.57% to close Monday at $3.13 after subtracting -$0.05 on the day. The 5-day average trading volume is 2,434,160 shares of the company’s common stock. It has gained $3.33 in the past week. An average of 4,278,715 shares of the company has been traded in the last 20 days, and the 50-day average volume stands at 6,191,448.
ATOS’s 1-month performance is -21.16% or -$0.84 on its low of $3.03 reached on 10/04/21. The company’s shares have touched a 52-week low of $0.81 and high of $9.80, with the stock’s rally to the 52-week high happening on 06/25/21. YTD, ATOS has achieved 229.47% or $2.18. However, the current price is down -68.06%% from the 52-week high price.
3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
On Jul 02, 102 days have gone by since the last insider trading activity for Atossa Therapeutics Inc. (ATOS). WEAVER GREGORY L (Director) most recently sold 107,497 shares at $5.58 per share on Jul 02. This transaction cost the insider $599,833.
Atossa Therapeutics Inc. (ATOS) has a trailing price-to-earnings (P/E) ratio of 34.65 for the broader industry and 32.24 for the sector.ATOS stock has a beta of 2.22. Moving on to other valuation ratios, the price-to-book (PB) in the most recent quarter is 2.65.
Atossa Therapeutics Inc.’s quick ratio for the period ended June 29 was 81.20, with the current ratio over the same period at 81.20 meaning that ATOS stock is able to fulfill its debt obligations. As well, the company’s long term debt to equity for the quarter ending June 29 was 0.00, while the total debt to equity was 0.00.
For the quarterly period ending June 29 this year, Analysts expected ATOS to announce -$0.03 per share in earnings in its latest quarter, but it posted -$0.06, representing a -100.00% surprise. ATOS stock balance sheet for the quarter ending June 29 shows that total liabilities totaled 1.8 million, with total debt at $4720.0. Shareholders hold equity totaling $126.62 million
Let’s look briefly at Atossa Therapeutics Inc. (ATOS) price momentum from a technical analysis perspective. The 9-day relative strength index as at close on 11 October was 42.75% to suggest the stock is trending Neutral, with historical volatility in this time period at 59.06%.
The stock’s 5-day moving average is $3.15, reflecting a +2.29% or $0.07 change from its current price. ATOS is currently trading -10.57% above its 20-day SMA, -3.10% above its 100-day SMA. However, the stock’s current price level is away from the SMA50 and SMA200 by +4.68% and +249.45% respectively.
Stochastic %K and %D was 32.03% and 26.62% and the average true range (ATR) pointed at 0.20. The RSI (14) points at 43.33%, while the 14-day stochastic is at 19.61% with the period’s ATR at 0.23. The stock’s 9-day MACD Oscillator is pointing at 0.03 and -0.05 on the 14-day charts.
In the most recent analyst report for Atossa Therapeutics Inc. (NASDAQ: ATOS), Maxim Group launched coverage with a Buy rating. Analysts offering their rating for ATOS stock have a consensus rating for the stock as Buy. Currently, 0 brokerage advisors rate ATOS as a “sell,”, while 0 advise that investors “Hold.” 0 analysts have rated the stock as underweight. 0 rates the stock as overweight while 2 have offered a “buy” rating.
What is ATOS’s price target for the next 12 months?
Analysts have a consensus price target ranging from a low of $7.00 and a high of $8.50, with their median price target at $7.75. Looking at these predictions, the average price target given by analysts is for Atossa Therapeutics Inc. (ATOS) stock is $7.75.